A drug currently used for the treatment of AIDS patients is showing promise in animal studies as a preventive, but the drug’s maker, Gilead, is keeping a low profile, based partly on fears that Truvada will be seen as a
biomedical condom
that might promote unsafe sex and lead to a backlash against a company that has become a Wall Street darling.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.